Turtle Cameron's Form 4 filing
Spyre Therapeutics, Inc. (SYRE) · filed Jan 6, 2026
- Accession no.
- 0001758363-26-000002
- Filed
- Jan 6, 2026
- Trade date
- Jan 2, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $460.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Turtle CameronCIK 0001758363 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Common Stock | SSaleDisposed | −12,709 | $30.47 | −$387,243.23 | 674,198 | Direct | |
| Jan 2, 2026 | Common Stock | SSaleDisposed | −2,191 | $31.79 | −$69,651.89 | 672,007 | Direct | |
| Jan 2, 2026 | Common Stock | SSaleDisposed | −100 | $32.39 | −$3,239 | 671,907 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.